Barclays Adjusts Price Target on Viatris to $15 From $16, Maintains Overweight Rating
11:15 AM EST, 02/01/2023 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co
Viatris Is Maintained at Overweight by Barclays
Viatris Price Target Cut to $15.00/Share From $16.00 by Barclays
Barclays Maintains Overweight on Viatris, Lowers Price Target to $15
Barclays analyst Balaji Prasad maintains Viatris with a Overweight and lowers the price target from $16 to $15.
Viatris Price Target Lowered to $15 From $16 at Barclays
Voices of Viatris: For Nathan Wilson, Family Is a Change Worth Fighting For
NORTHAMPTON, MA / ACCESSWIRE / January 31, 2023 / Viatris:When Nathan Wilson was just 19, he was violently attacked by strangers one evening while walking in a town in New South Wales, Australia. Seri
Where Viatris Stands With Analysts
Analysts have provided the following ratings for Viatris (NASDAQ:VTRS) within the last quarter: BullishSomewhat BullishIndifferentSomewhat BearishBearishTotal Ratings10300Last 30D100001M Ago000002M Ag
Viatris' Farxiga Generic Gets EMA Committee's Backing for Approval in EU
Viatris Price Target Raised to $15.00/Share From $13.00 by Jefferies
Viatris Raised to Buy From Hold by Jefferies
Loading...
No Stock Yet